| abstract |
The present invention provides chromium compounds which possess the ability to improve insulin sensitization, glucose tolerance, blood lipid metabolism, lean body mass, bioavailability, and safety as compared to chromium nicotinate, chromium picolinate and chromium histidine. These compounds are screened in terms of solubility, in vitro insulin sensitization, stability, and absorption as compared to chromium nicotinate, chromium picolinate and chromium histidine. The most promising chromium compounds are tested for their animal in vivo bioavailability, glucose metabolism, lipid metabolism and acute toxicity. |